Thanh bên bài viết

PDF
Ngày xuất bản: 11/09/2021
Số lượt xem tóm tắt: 217
Số lượt xem PDF: 132
DOI: https://doi.org/10.51298/vmj.v506i1-2.988
Số xuất bản
Tập 506 Số 1-2 (2021): Vietnam Medical Journal
Chuyên mục
Các bài báo
Trích dẫn bài báo
Duy Thang, N. ., Thi Thuy Hoa, P. ., Thi Dieu Ngan, P. ., Nhat Hoang, N. ., & Thi Cam Ha, C. . (2021). MESENCHYMAL STEM CELL-BASED THERAPY FOR CHRONIC KIDNEY FAILURE RELATING LUPUS ERYTHEMATOSUS - A CASE REPORT. Tạp Chí Y học Việt Nam, 506(1-2). https://doi.org/10.51298/vmj.v506i1-2.988

MESENCHYMAL STEM CELL-BASED THERAPY FOR CHRONIC KIDNEY FAILURE RELATING LUPUS ERYTHEMATOSUS - A CASE REPORT

Duy Thang Nguyen 1, Thi Thuy Hoa Phan 1, Thi Dieu Ngan Phan 2, Nhat Hoang Ngo 2, Thi Cam Ha Che 2,
1 Hue Central Hospital
2 Hue University

Nội dung chính của bài viết

Tóm tắt

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, which is characterized by systemic multiple-organ involvement, relapses with large amount of autoantibodies. Their pathophysiology is multifaceted, involves complex hormonal-immunological-cellular interactions, and leads to damage in multiple cell types, which is often resistant to conventional therapy. Thus, novel strategies are needed to repair the renal parenchyma and preserve kidney function. Mesenchymal stem cells (MSC) confer renal protection through paracrine/endocrine effects, and to some degree possibly by direct engraftment. The patient was diagnosed with chronic kidney disease by standard methods for more than fifteen years. The patient agreed to the treatment of autologous adipose mesenchymal stem cell transplantation. The adipose mesenchymal stem cells were harvested by surgery, isolated with our enzyme protocol. The patient received one injection with 2,6x106 cells/kg for a total of 43kg of body weight. The patient with SLE do not receive prompt treatment, he get irreversible organ damage. After seven months, the preexisting renal insufficiency gradually ameliorated, including the decrease of creatinine and blood urea as well as the increase of estimated glomerular filtration rate. Lupus symptoms also reduced, followed by the improvement of body movement and medication reduction.There was insufficient evidence of the clinical setting to show the efficiency of mesenchymal stem cells on the lupus nephritis relating to chronic kidney disease.  This clinical trial highlights the feasibility and safety of mesenchymal stem cell treatments in renal failure-associated- autoimmune diseases.

Chi tiết bài viết

Từ khóa

Mesenchymal stem cells, adipose tissue, chronic kidney failure, lupus erythematosus, transplantation, autoimmune disease

Tài liệu tham khảo

1. SALAMA AD, CAPLIN B. Lupus Nephritis and Chronic Kidney Disease. 2020;47(9):1303-4.
2. Orr SE, Bridges CC. Chronic Kidney Disease and Exposure to Nephrotoxic Metals. International journal of molecular sciences. 2017;18(5).
3. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, et al. Chronic kidney disease. Nature Reviews Disease Primers. 2017;3(1):17088.
4. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.
5. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood. 2007;109(9):4055-63.
6. Monsel A, Zhu Y-G, Gennai S, Hao Q, Liu J, Lee JW. Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells. Anesthesiology. 2014;121(5):1099-121.
7. Sun LY, Zhou KX, Feng XB, Zhang HY, Ding XQ, Jin O, et al. Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus. Clinical rheumatology. 2007;26(12):2073-9.
8. Elhusseini FM, Saad M-AAA, Anber N, Elghannam D, Sobh M-A, Alsayed A, et al. Long Term Study of Protective Mechanisms of Human Adipose Derived Mesenchymal Stem Cells on Cisplatin Induced Kidney injury in Sprague-Dawley Rats. J Stem Cells Regen Med. 2016;12(1):36-48.
9. Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cellular & molecular immunology. 2008;5(6):417-24.
10. Peired AJ, Sisti A, Romagnani P. Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence. Stem Cells International. 2016;2016:4798639.
11. Erpicum P, Detry O, Weekers L, Bonvoisin C, Lechanteur C, Briquet A, et al. Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrology Dialysis Transplantation. 2014;29(8):1487-93.
12. Asari S, Itakura S, Ferreri K, Liu C-P, Kuroda Y, Kandeel F, et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 2009;37(5):604-15.
13. Eirin A, Lerman LO. Mesenchymal stem cell treatment for chronic renal failure. Stem Cell Res Ther. 2014;5(4):83-.
14. Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney international. 2006;70(1):121-9.
15. Huang JL, Woolf AS, Kolatsi-Joannou M, Baluk P, Sandford RN, Peters DJ, et al. Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases. Journal of the American Society of Nephrology : JASN. 2016;27(1):69-77.
16. Gu F, Molano I, Ruiz P, Sun L, Gilkeson GS. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice. Clinical immunology (Orlando, Fla). 2012;145(2):142-52.
17. Steinert AF, Ghivizzani SC, Rethwilm A, Tuan RS, Evans CH, Nöth U. Major biological obstacles for persistent cell-based regeneration of articular cartilage. Arthritis Research & Therapy. 2007;9(3):213.
18. Gómez-Aristizábal A, Sharma A, Bakooshli MA, Kapoor M, Gilbert PM, Viswanathan S, et al. Stage-specific differences in secretory profile of mesenchymal stromal cells (MSCs) subjected to early- vs late-stage OA synovial fluid. Osteoarthritis and Cartilage. 2017;25(5):737-41.
19. Kocsis JD, Honmou O. Chapter 6 - Bone marrow stem cells in experimental stroke. In: Dunnett SB, Björklund A, editors. Progress in Brain Research. 201: Elsevier; 2012. p. 79-98.
20. Activated NF-κB in Bone Marrow Mesenchymal Stem Cells from Systemic Lupus Erythematosus Patients Inhibits Osteogenic Differentiation Through Downregulating Smad Signaling. 2013;22(4):668-78.
21. Gao L, Bird AK, Meednu N, Dauenhauer K, Liesveld J, Anolik J, et al. Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-β Feedback Loop. Arthritis Rheumatol. 2017;69(8):1623-35.
22. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis and rheumatism. 2005;52(8):2521-9.
23. Villanueva S, González F, Lorca E, Tapia A, López VG, Strodthoff R, et al. Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility. Kidney Res Clin Pract. 2019;38(2):176-85.